Anixa Biosciences (ANIX) News Today $2.75 +0.02 (+0.73%) As of 05/21/2026 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Anixa Biosciences (ANIX) to Release Earnings on WednesdayMay 20 at 2:15 AM | americanbankingnews.com/C O R R E C T I O N -- Anixa Biosciences, Inc./May 13, 2026 | finance.yahoo.comAnixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T TherapyMay 11, 2026 | prnewswire.comAnixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street ZenMay 2, 2026 | marketbeat.comAnixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TVMay 1, 2026 | prnewswire.comAnixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine TechnologyApril 29, 2026 | prnewswire.comAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual MeetingApril 22, 2026 | prnewswire.comAnixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026April 9, 2026 | prnewswire.comAnixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026April 7, 2026 | prnewswire.comAnixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy ProgramsApril 6, 2026 | prnewswire.comAnixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP ManufacturingApril 1, 2026 | prnewswire.comAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's CancerMarch 30, 2026 | prnewswire.comAnixa Biosciences Featured on Water Tower Research Healthcare Happenings PodcastMarch 12, 2026 | prnewswire.comAnixa Biosciences Inc.March 11, 2026 | barrons.comAnixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine TechnologyMarch 9, 2026 | prnewswire.comAnixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory ProgressMarch 2, 2026 | prnewswire.comAnixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 RetreatFebruary 23, 2026 | prnewswire.comAnixa Biosciences, Inc.: Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose ...February 9, 2026 | finanznachrichten.deAnixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose EscalationFebruary 9, 2026 | prnewswire.comEXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety IssuesFebruary 9, 2026 | benzinga.comAnixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future CommercializationFebruary 2, 2026 | prnewswire.comArnold Baskies Purchases 10,000 Shares of Anixa Biosciences (NASDAQ:ANIX) StockJanuary 30, 2026 | insidertrades.comAnixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine TechnologyJanuary 27, 2026 | prnewswire.comAnixa announces transfer of IND for breast cancer vaccine from Cleveland ClinicDecember 15, 2025 | msn.comAnixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland ClinicDecember 15, 2025 | prnewswire.comD Boral Capital maintains Anixa Biosciences (ANIX) buy recommendationDecember 13, 2025 | msn.comAnixa Biosciences, Inc.: Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in ...December 12, 2025 | finanznachrichten.deAnixa Biosciences says all primary endpoints met in breast cancer vaccine trialDecember 11, 2025 | msn.comCleveland Clinic researchers share promising results from experimental breast cancer vaccine trialDecember 11, 2025 | msn.comAnixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of ParticipantsDecember 11, 2025 | prnewswire.comAnixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025December 10, 2025 | prnewswire.comAnixa Biosciences (ANIX) Price Target Increased by 11.11% to 10.20November 18, 2025 | msn.comAnixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs TranscriptNovember 17, 2025 | seekingalpha.comAnixa Biosciences’ CAR-T therapy granted WHO approval of non-proprietary nameNovember 17, 2025 | msn.comAnixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global ...November 17, 2025 | finance.yahoo.comAnixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future CommercializationNovember 17, 2025 | prnewswire.comTop Penny Stocks To Watch In November 2025November 13, 2025 | uk.finance.yahoo.comWater Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside ChatNovember 12, 2025 | globenewswire.comAnixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040sNovember 12, 2025 | prnewswire.comAnixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025November 10, 2025 | prnewswire.comAnixa Biosciences executes data transfer with Cleveland ClinicNovember 5, 2025 | msn.comAnixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland ClinicNovember 5, 2025 | prnewswire.comAnixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor ConferenceOctober 23, 2025 | prnewswire.comAnixa Biosciences stock rises after securing Chinese patent for cancer vaccineOctober 20, 2025 | in.investing.comAnixa awarded patent in China covering breast cancer vaccine technologyOctober 20, 2025 | msn.comAnixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine TechnologyOctober 20, 2025 | prnewswire.comOctober 2025 Penny Stocks With Promising PotentialOctober 15, 2025 | finance.yahoo.comD. Boral Capital Maintains Anixa Biosciences (ANIX) Buy RecommendationOctober 8, 2025 | msn.comAnixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical TrialOctober 7, 2025 | prnewswire.comAnixa announces final results from Phase 1 trial of breast cancer vaccineSeptember 22, 2025 | msn.com Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIX Media Mentions By Week ANIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIX News Sentiment▼0.000.40▲Average Medical News Sentiment ANIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIX Articles This Week▼13▲ANIX Articles Average Week Get the Latest News and Ratings for ANIX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Anixa Biosciences and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Altimmune News Rocket Pharmaceuticals News Cellectis News Puma Biotechnology News SNDL News Ovid Therapeutics News Opus Genetics News SOPHiA GENETICS News Siga Technologies News DiaMedica Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIX) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
